Life Sciences Blog

Eli Lilly to market Strides Arcolab generic cancer drugs

Posted on December 6th, by Michael Shapiro-Barr

Eli Lilly & Co. and Strides Arcolab have signed an agreement which will mean that Eli Lilly will market the Indian partner’s branded generic cancer drugs in emerging markets.  Managing director for Lilly India has stated that the partnership will help Eli Lilly gain a more meaningful presence in the Indian cancer drug segment.

Read More



Comments are closed.

Recent Posts

Enter your email address to subscribe to this blog and receive notifications of new posts by email.


From the Blog

Where to Spend Your Healthcare Investment Dollars

In a blog entry written over the summer, I expressed the view that the next 5-10 years will present tremendous transactional opportunities in the life...

Second Circuit Rejects Government’s Off-Label Enforcement Approach

Last week’s decision in the off-label promotion case, United States v. Caronia, No. 09-5006-cr (2d Cir. Dec. 3, 2012), is an important blow to...

Massachusetts Refines Its Sunshine Law; Final Federal Sunshine Regulations Moving Ahead

The relationship between health care providers and drug and device manufacturers has been a focus of lawmakers at both the federal and state level. ...

Subscribe by Email for New Blog Posts